Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.56 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7984035 | 0.83 | L3MBTL1 (0.78) | L3MBTL1SMN1; SMN2GAAPKMHSD17B1 | |
| SCHEMBL3625980 | 0.82 | L3MBTL1 (0.69) | L3MBTL1SMN1; SMN2GAAPKMHSD17B1 | |
| SCHEMBL6833577 | 0.82 | L3MBTL1 (0.59) | L3MBTL1SMN1; SMN2GAAPKMHSD17B1 | |
| SCHEMBL6834556 | 0.82 | L3MBTL1 (0.59) | L3MBTL1SMN1; SMN2GAAPKMHSD17B1 | |
| SCHEMBL5212867 | 0.80 | L3MBTL1 (0.57) | L3MBTL1SMN1; SMN2GAAPKMHSD17B1 | |
| SCHEMBL13602263 | 0.80 | L3MBTL1 (0.63) | L3MBTL1SMN1; SMN2GAAPKMTHRB | |
| SCHEMBL23093376 | 0.80 | KDM1A (0.62) | SMN1; SMN2GAAALDH1A1CA2HTT | |
| SCHEMBL176826 | 0.80 | L3MBTL1 (0.66) | L3MBTL1SMN1; SMN2GAAPKMHSD17B1 | |
| SCHEMBL410747 | 0.79 | AR (0.67) | L3MBTL1SMN1; SMN2GAAPKMTHRB | |
| SCHEMBL31235173 | 0.79 | AR (0.67) | L3MBTL1SMN1; SMN2GAAPKMTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785499-B2 | Targeting NAD biosynthesis in bacterial pathogens | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120190708-A1 | TARGETING NAD BIOSYNTHESIS IN BACTERIAL PATHOGENS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2012-07-26 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | L3MBTL1 3597/4885SMN1; SMN2 4811/4885GAA 1381/4885 |
| US-20120190708-A1 | TARGETING NAD BIOSYNTHESIS IN BACTERIAL PATHOGENS | NAMPT, NAPRT, NADK | L3MBTL1 1449/4885SMN1; SMN2 4145/4885GAA 1159/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | L3MBTL1 3597/4885SMN1; SMN2 4811/4885GAA 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.